12:00 AM
 | 
Sep 09, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/6 cls
Pharmacyclics Inc. (NASDAQ:PCYC) Lazard Joshua Schimmer Upgrade Buy (from neutral) 6% $117.74
Schimmer also set a $141 target after a handful of community hematology and oncology specialists said ibrutinib could reach over $5B in global sales "far faster than the 2020 modeled by consensus." He expects 2020 worldwide sales at $3B-$11B. An NDA for the Bruton's...

Read the full 484 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >